Atossa Therapeutics, Inc.

Equities

ATOS

US04962H5063

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
1.61 ^USD	0.00%		-4.73%	+82.95%

May. 15	Atossa Therapeutics Doses Last Patient in Phase 2 Karisma-Endoxifen Trial	MT
May. 15	Atossa Therapeutics, Inc. Announces Last Patient, Last Dose in Its Phase 2 Karisma-Endoxifen Clinical Trial	CI

Atossa Genetics Announces Resignation of Scott Youmans as a Chief Operating Officer, Effective February 12, 2016

February 08, 2016 at 04:42 pm EST

On February 3, 2016, Scott Youmans announced that he is departing as the Chief Operating Officer of Atossa Genetics Inc. with an expected effective date of February 12, 2016. Mr. Youmans is pursuing other professional activities.

Latest news about Atossa Therapeutics, Inc.

Atossa Therapeutics Doses Last Patient in Phase 2 Karisma-Endoxifen Trial	May. 15	MT
Atossa Therapeutics, Inc. Announces Last Patient, Last Dose in Its Phase 2 Karisma-Endoxifen Clinical Trial	May. 15	CI
Atossa Therapeutics Files $100 Million Mixed-Shelf Offering	May. 13	MT
Atossa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Atossa Therapeutics, Inc. Announces Support of New Breast Cancer Screening Guidelines by U.S. Preventive Services Task Force	May. 07	CI
Atossa Therapeutics, Inc. Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates and (Z)-Endoxifen	Apr. 29	CI
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Announces I-SPY 2 Clinical Trial to Evaluate (Z-Endoxifen in Combination with Abemaciclib (VERZENIO®?) in Women with ER+/HER2- Breast Cancer	Apr. 15	CI
Atossa Therapeutics, Inc. Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen	Apr. 09	CI
North American Morning Briefing : Stocks Seen -2-	Apr. 02	DJ
Atossa Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for A U.S. Breast Cancer Patient	Mar. 19	CI
Atossa Therapeutics Appoints Tessa Cigler to Its Board of Directors	Mar. 12	CI
Atossa Therapeutics, Inc. Announces First Patient Dosed with Selective Estrogen Receptor Modulator in the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment	Feb. 22	CI
Atossa Therapeutics Rises After HC Wainwright Starts Coverage with Buy Rating	Feb. 12	MT
HC Wainwright Initiates Atossa Therapeutics With Buy Rating, Price Target is $4	Feb. 12	MT
Atossa Therapeutics, Inc. Announces Full Enrollment of (Z) -Endoxifen Arm of I-Spy 2 Clinical Trial	Feb. 07	CI
Atossa Therapeutics, Inc.'s Equity Buyback announced on June 27, 2023, has expired with 1,320,046 shares, representing 1.04% for $1.44 million.	Dec. 30	CI
Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director	Dec. 04	CI
Atossa Therapeutics Says Full Enrollment Reached in Karisma-Endoxifen Trial of Breast-Cancer Drug	Nov. 20	MT
Atossa Therapeutics, Inc. Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial	Nov. 20	CI
Tranche Update on Atossa Therapeutics, Inc.'s Equity Buyback Plan announced on June 27, 2023.	Nov. 13	CI
Atossa Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Atossa Therapeutics, Inc. Appoints Jonathan Finn to Its Board of Directors	Nov. 10	CI
North American Morning Briefing : Investors Weigh -2-	Nov. 10	DJ
Atossa Therapeutics, Inc. Appoints Jonathan Finn to Its Board of Directors	Nov. 09	CI

Chart Atossa Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).

Sector

Biotechnology & Medical Research

Calendar

2024-08-13 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.61 USD

Average target price

4.667 USD

Spread / Average Target

+189.86%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ATOSSA THERAPEUTICS, INC.	+82.95%	202M
MODERNA, INC.	+33.37%	49.46B
IQVIA HOLDINGS INC.	+1.55%	42.58B
LONZA GROUP AG	+49.11%	42.49B
CELLTRION, INC.	-4.22%	29.09B
ICON PUBLIC LIMITED COMPANY	+11.57%	26.61B
ALNYLAM PHARMACEUTICALS, INC.	-21.00%	18.64B
BIO-TECHNE CORPORATION	+7.36%	13.16B
MEDPACE HOLDINGS, INC.	+28.30%	12.55B
UNITED THERAPEUTICS CORPORATION	+23.80%	12.1B

Other Biotechnology & Medical Research